Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Enanta Pharmaceutica (ENTA)

Enanta Pharmaceutica (ENTA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 911,579
  • Shares Outstanding, K 20,713
  • Annual Sales, $ 97,070 K
  • Annual Income, $ -79,000 K
  • 60-Month Beta 0.64
  • Price/Sales 9.81
  • Price/Cash Flow N/A
  • Price/Book 2.66
Trade ENTA with:

Options Overview Details

View History
  • Implied Volatility 90.46% ( -0.29%)
  • Historical Volatility 56.87%
  • IV Percentile 92%
  • IV Rank 50.27%
  • IV High 146.27% on 05/18/22
  • IV Low 34.05% on 08/19/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 26
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 1,187
  • Open Int (30-Day) 795

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -1.45
  • Number of Estimates 6
  • High Estimate -1.05
  • Low Estimate -1.75
  • Prior Year -1.19
  • Growth Rate Est. (year over year) -21.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.02 +10.07%
on 05/19/22
76.62 -45.38%
on 04/21/22
-33.94 (-44.78%)
since 04/20/22
3-Month
38.02 +10.07%
on 05/19/22
79.50 -47.36%
on 04/07/22
-22.54 (-35.01%)
since 02/18/22
52-Week
38.02 +10.07%
on 05/19/22
102.00 -58.97%
on 11/05/21
-6.81 (-14.00%)
since 05/20/21

Most Recent Stories

More News
Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops

While a mid-stage study evaluating Enanta's (ENTA) RSV candidate misses out on its primary endpoint, a statistically huge number of subjects achieved undetectable RSV RNA at the end of treatment.

PFE : 52.47 (+3.59%)
ALKS : 30.00 (+1.76%)
ENTA : 41.87 (-4.86%)
ABEO : 0.1560 (-7.96%)
Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported topline results for...

ENTA : 41.87 (-4.86%)
Enanta Pharmaceuticals (ENTA) Q2 2022 Earnings Call Transcript

ENTA earnings call for the period ending March 31, 2022.

ENTA : 41.87 (-4.86%)
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -13.99% and 8.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ENTA : 41.87 (-4.86%)
CPRX : 7.06 (+2.02%)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET

Enanta Pharmaceuticals, Inc . (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results...

ENTA : 41.87 (-4.86%)
Xencor (XNCR) Beats Q1 Earnings and Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of 155.71% and 302.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

XNCR : 23.55 (+2.48%)
ENTA : 41.87 (-4.86%)
Enanta Pharmaceuticals to Host Conference Call on May 9 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2022

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to...

ENTA : 41.87 (-4.86%)
Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

Enanta Pharmaceuticals, Inc . (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the U.S. Food...

ENTA : 41.87 (-4.86%)
Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938 for the Treatment of Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals, Inc . (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that data from its...

ENTA : 41.87 (-4.86%)
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

Enanta Pharmaceuticals, Inc . (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has dosed...

ENTA : 41.87 (-4.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown,...

See More

Key Turning Points

3rd Resistance Point 52.60
2nd Resistance Point 48.49
1st Resistance Point 46.25
Last Price 41.87
1st Support Level 39.90
2nd Support Level 35.78
3rd Support Level 33.54

See More

52-Week High 102.00
Fibonacci 61.8% 77.56
Fibonacci 50% 70.01
Fibonacci 38.2% 62.46
Last Price 41.87
52-Week Low 38.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar